

Chlorambucil

Dr. Andrew Mackin, Mississippi State University

Chlorambucil is a nitrogen mustard derivative cell-cycle nonspecific alkylating agent that has, for many decades, been used in both human and veterinary medicine predominantly as an antineoplastic agent for the treatment of cancers such as lymphoid leukemia, lymphoma, mast cell tumors, multiple myeloma and polycythemia vera. Antineoplastic cytotoxicity is derived from inappropriate cross-linkage of cellular DNA and RNA by insertion of alkyl radicals on the purine base, guanine. Chlorambucil also has immunosuppressive properties, and has occasionally been used in human medicine to treat immune-mediated and inflammatory conditions such as glomerulonephritis. More than 30 years ago, some veterinary clinicians began suggesting the use of chlorambucil as an immunosuppressive agent for our small animal patients. Since then, the use of chlorambucil for the treatment of a number of feline inflammatory skin conditions, such as pemphigus foliaceus (Irwin; Mundell; Preziosi; Rosenkrantz; Thodes) and eosinophilic granuloma complex (Foster), and for treatment of diseases such as immune-mediated thrombocytopenia (Wondratschek) and refractory inflammatory bowel disease, has become very well established, primarily because of a paucity of viable alternative medications that could be accurately dosed with safety in cats. The use of chlorambucil as immunosuppressive agent in dogs has been slower to evolve, but its use has been described for the treatment of pemphigus (Mundell; Rosenkrantz), glomerulonephritis (Segev) and, most recently, inflammatory bowel disease (Marks; Dandrieux). It is somewhat surprising that chlorambucil has not attained more common usage as an immunosuppressive agent in dogs, since it appears to have much the same mechanism of action as cyclophosphamide with significantly less onerous side effects (specifically, chlorambucil does not cause sterile cystitis), and comes in a more convenient tablet size.

Chlorambucil is metabolized predominantly in the liver, primarily to the active metabolite phenylacetic acid mustard. Compared to other alkylating agents, chlorambucil is relatively well tolerated, especially at immunosuppressive doses, but does occasionally cause gastrointestinal side effects such as vomiting and diarrhea, and/or myelosuppression with neutropenia, thrombocytopenia and non-regenerative anemia (anemia is usually mild). Alopecia and poor hair growth are sometimes reported in susceptible dog breeds, such as poodles. Neurologic side effects are reported with chronic chlorambucil use in people, and chlorambucil-associated neurologic signs (including myoclonus, twitches and seizures) have been reported in cats (Benitah).

Chlorambucil is available as a coated 2 mg tablet that cannot feasibly be divided, and dosing recommendations in smaller patients are therefore typically provided in multiples of two, and/or 'pulsed' at infrequent dosing intervals (given at an interval that ensures the overall weekly dose is equivalent to seven times the calculated daily dose) in order to avoid overdose. For immunosuppressive therapy, chlorambucil is almost always given in combination with an oral

glucocorticoid. In dogs, recommended starting oral immunosuppressive chlorambucil doses (with a glucocorticoid) range from 0.1 to 0.2 mg/kg (or, alternatively, 4 to 6 mg/m²) every one to two days, with dosing individualized based on patient size and disease severity. In cats (and small dogs) with inflammatory or immune-mediated disease, a starting oral chlorambucil dose of 2 mg every second day (with a glucocorticoid), tapered to every 3rd or 4th day, is my preferred dosing regime, although a number of other tapered dosing protocols are also available. Lower daily doses of chlorambucil, comparable to dog dosing regimes, can also be used in cats if the drug is compounded, but the effects of compounding on drug efficacy have not been established. Complete blood counts must be monitored regularly (weekly at first) and, since myelosuppression tends to be dose-dependent rather than idiosyncratic, doses can be tapered 'to effect' rather than discontinued completely. Myelosuppression, provided it is detected promptly, is typically reversible (Irwin; Mundell).

Compared to many other immunosuppressive agents, chlorambucil has until recently been moderately priced. Unfortunately, the patent on the only available chlorambucil product, Leukeran[®], recently expired, leading to a change in ownership of the company responsible for distributing the drug, and the US price of chlorambucil has doubled as a result, to over \$10 for a 2 mg tablet. There are currently no other US generic alternatives, apart from compounded products.

- Benitah N, de Lorimier L, Gaspar M, Kitchell B. Chlorambucil-induced myoclonus in a cat with lymphoma. *Journal of the American Animal Hospital Association*. May 2003;39(3):283-287.
- Dandrieux J, Noble P, Scase T, Cripps P, German A. Comparison of a chlorambucil-prednisolone combination with an azathioprine-prednisolone combination for treatment of chronic enteropathy with concurrent protein-losing enteropathy in dogs: 27 cases (2007-2010). *Journal of the American Veterinary Medical Association*. June 15, 2013;242(12):1705-1714.
- Irwin K, Beale K, Fadok V. Use of modified ciclosporin in the management of feline pemphigus foliaceus: a retrospective analysis. *Veterinary Dermatology*. October 2012;23(5):403-e76
- Marks S. Management of canine inflammatory bowel disease. *Compendium on Continuing Education for the Practicing Veterinarian*. March 1998;20(3):317-332.
- Mundell A. New therapeutic agents in veterinary dermatology. *The Veterinary Clinics of North America. Small Animal Practice*. November 1990;20(6):1541-1556.
- Preziosi D, Goldschmidt M, Mauldin E, et al. Feline pemphigus foliaceus: A retrospective analysis of 57 cases. *Veterinary Dermatology*. December 2003;14(6):313-321.
- Rosenkrantz W. Pemphigus: Current therapy. *Veterinary Dermatology*. April 2004;15(2):90-98.

- Segev G, Cowgill L, Heiene R, Labato M, Polzin D. Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology. *Journal of Veterinary Internal Medicine*. 2013;27(s1):S44-S54.
- Thodes K, Shoulberg N. Chlorambucil: effective therapeutic options for the treatment of feline immune-mediated dermatoses. *Feline Practice*. 1992;20(3):5-8.
- Wondratschek C, Weingart C, Kohn B. Primary immune-mediated thrombocytopenia in cats. *Journal of the American Animal Hospital Association*. January 2010;46(1):12-19.